A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Intracisternal Engineered Autologous Exosomes (NV-101) to Restore Neuronal Proteostasis in Early Alzheimer’s Disease: The RESTORE Protocol
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
The current therapeutic landscape for Alzheimer’s disease (AD) offers limited efficacy. The failure of the neuronal proteostasis network a system critical for preventing toxic protein aggregation is a fundamental pathological process in AD. Molecular chaperones, which are deficient in the AD brain, represent a compelling therapeutic target. A major obstacle has been delivering large biologics like chaperones across the blood-brain barrier. Engineered exosomes offer a promising platform for neuron-specific delivery of nucleic acid cargo.
Objective
The primary objective is to evaluate the safety and tolerability of a single intracisternal dose of NV-101, an autologous dendritic cell-derived exosome engineered with neuron-targeting peptides and DNAJB6 mRNA, compared to placebo in participants with early AD. Secondary objectives are to assess its biological activity through cerebrospinal fluid (CSF) biomarkers.
Methods
The RESTORE trial is a single-center, randomized, double-blind, placebo-controlled, dose-escalation study. Eighteen participants with biomarker-confirmed early AD will be enrolled across three sequential dose cohorts (Low, Medium, High). Participants will be randomized in a 2:1 ratio to receive either NV-101 or placebo (excipient buffer) via a single intracisternal magna injection. The primary outcome is the incidence of treatment-emergent adverse events over 52 weeks. Secondary outcomes include change from baseline in CSF levels of DNAJB6 protein, oligomeric amyloid-β42, and phosphorylated tau (p-tau181). Exploratory outcomes include neuroimaging and cognitive measures.
Conclusions
This first-in-human study will generate critical safety and initial proof-of-mechanism data for a novel therapeutic strategy aimed at correcting proteostatic failure in AD.
